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Abstract
Introduction: Ductal and lobular carcinomas are the two most common types of invasive breast cancer. Whether
well-established risk factors are differentially associated with risk on the basis of histologic subtype is not clear. We
prospectively investigated the association between a number of hormonal and nonhormonal exposures and risk
defined by histologic subtype among 4,655 ductal and 659 lobular cases of postmenopausal breast cancer from
the Nurses’ Health Study.
Methods: Multivariate Cox proportional hazards regression stratified by histologic subtype and time period was
used to examine the association between risk factors and the incidence of ductal and lobular subtypes. For each
exposure, we calculated the P value for heterogeneity using a likelihood ratio test comparing models with separate
estimates for the two subtypes versus a single estimate across subtypes.
Results: The associations with age at menarche (P-heterogeneity (het) = 0.03), age at first birth (P-het < 0.001) and
postmenopausal hormone use (P-het < 0.001) were more strongly associated with lobular cancers. The associations
with age, nulliparity, parity, age at menopause, type of menopause, alcohol intake, adult body mass index (BMI),
BMI at age 18, family history of breast cancer and personal history of benign breast disease did not vary by
subtype (P-het ≥ 0.08). Results were similar when we restricted the analyses to estrogen receptor-positive and
progesterone receptor-positive tumors.
Conclusions: These data indicate that breast cancer is a heterogeneous disease, and the differential association
with a number of risk factors is suggestive of etiologically distinct tumors. Epidemiological analyses should
continue to take into account a modifying role of histology.
Introduction
Epidemiologic studies have shown that reproductive,
lifestyle and anthropometric exposures are predictive of
subsequent breast cancer risk [1,2]; however, whether
these factors are differentially associated with risk on
the basis of histologic subtype is not clear. Among inva-
sive breast cancer cases, ~75% are ductal carcinomas,
15% are of the lobular type and the remainder are a mix
of other, less common histologies [3]. Differences in
clinical, molecular and pathologic features of ductal and
lobular tumors [4] suggest a distinct etiology and may
have implications with respect to their prevention,
diagnosis and treatment. Further, lobular cancers are
more likely than ductal cancers to be estrogen receptor
(ER)-positive and progesterone receptor (PR)-positive
[5,6]. This might explain why several studies have
demonstrated differences in the association between
postmenopausal hormone use (PMH) and risk of breast
cancer by histology, with a stronger effect seen for lobu-
lar carcinomas [7].
Besides the studies of PMH and breast cancer risk by
histology, few large studies have evaluated whether the
association of other well-established breast cancer risk
factors varies by histology [8-10]. Moreover, limitations
of prior studies include the lack of formal statistical test-
ing across disease subtypes, small sample size, no con-
trol for ER or PR status or the use of retrospective data.
Therefore, we prospectively examined the relationship
between known breast cancer risk factors and their
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breast cancers, ductal and lobular, diagnosed among
postmenopausal women from the Nurses’ Health Study
(NHS) cohort.
Materials and methods
Study population
The NHS was initiated in 1976, when 121,700 female
registered nurses between the ages of 30 and 55 and
residing in 11 U.S. states completed a self-administered,
mailed questionnaire about their medical histories and
health-related exposures [11-13]. Every 2 years, follow-
up questionnaires have been mailed to update informa-
tion on risk factors and disease development. A food
frequency questionnaire was added in 1980, and subse-
quent dietary questionnaires were distributed in 1984,
1986 and every 4 years thereafter. We defined baseline
as 1980, the first time we assessed alcohol intake (n =
92,468). Follow-up has been high in this cohort (95.2%
of the total possible person-years through June 2006).
The study protocol was approved by the Institutional
Review Board at Brigham and Women’s Hospital.
Exposure data
We obtained information on the exposures of interest
from one or more of the biennial questionnaires com-
pleted by participants. On the baseline questionnaire, we
collected information on date of birth, age at menarche,
weight at age 18 and current height. The baseline and
all subsequent questionnaires requested information on
status and duration of PMH use, menopausal status,
type of menopause, history of benign breast disease
(BBD) and current weight as well as, beginning in 1978,
the type of PMH.
For the other exposures of interest, questions were
included on multiple but not all questionnaires, and we
updated the value for each covariate when new informa-
tion was available or otherwise carried forward the value
from the previous follow-up cycle. For the exposures
that were collected at a single time point (for example,
age at menarche), we carried forward the value through-
out the remainder of follow-up. Age at menopause was
requested on all questionnaires through 2000 and meno-
pausal status was included on all questionnaires through
2002, at which time the youngest participants were 55
years of age. We assessed age at first birth (AFB) and
parity on every NHS questionnaire until 1984 and again
in 1996 to update the data on each woman’s lifetime
pregnancy history. Data on family history of breast can-
cer in a first-degree relative were collected every 4 to
8 years beginning in 1976. Daily alcohol consumption
was first queried in 1980, then in 1984 and 1986 and
every 4 years thereafter.
Identification of breast cancer cases
The primary end point was the diagnosis of invasive
ductal or invasive lobular breast cancer. Carcinomas
in situ were censored. On each questionnaire, we asked
whether breast cancer had been diagnosed and, if so,
the date of diagnosis. We asked all women who reported
breast cancer (or next of kin for those who had died) for
written consent to review the pertinent medical records
for confirmation. We also searched the National Death
Index for breast cancer deaths among women who did
not respond to the questionnaires, which accounted for
less than 1% of confirmed breast cancer cases. Pathology
reports or cancer registry data were obtained for 95% of
the cases. Histologic type and ER or PR status were
based upon extraction from the medical records. Inva-
sive tumors of mixed ductal and lobular type or of other
or unknown histology were censored at the date of
diagnosis.
Exclusions
We excluded the following w o m e na tb a s e l i n ef r o mt h e
analysis: those reporting a previous diagnosis of ductal
carcinoma in situ (DCIS; n = 26) or any invasive cancer
except nonmelanoma skin cancer (n = 4,933), those
reporting no year of birth (n = 161) and those who died
before 1980 (n = 461). Women were censored at the time
of development of DCIS or any type of invasive cancer
except nonmelanoma skin cancer. Only postmenopausal
women were included in the analysis, because the analy-
sis included many hormonal factors that may operate dif-
ferently in pre- and postmenopausal women, and we had
limited numbers of woman with premenopausal lobular
breast cancers. Women who were premenopausal at
baseline began contributing person-time to the analysis
at the time that they became postmenopausal. Meno-
pause was defined as natural, radiation-induced (very few
women had radiation-induced menopause: ~0.14%) or
surgical (hysterectomy with or without unilateral or bilat-
eral oophorectomy).
Statistical analysis
Participants accrued person-time from the return date
o ft h eb a s e l i n eq u e s t i o n n a i r eu n t i lt h ed a t eo fb r e a s t
cancer diagnosis, diagnosis of any other cancer (exclud-
ing nonmelanoma skin cancer), death or the end of fol-
low-up (2006). Participants contributed person-time
only for follow-up periods for which they were postme-
nopausal. For the reproductive and hormonal exposures,
we modeled age, age at menarche and age at menopause
as continuous variables to minimize the number of
parameters in the model. We used categorical variables
to model type of menopause (natural or radiation-
induced, surgical with two ovaries removed, surgical
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parous or parous, AFB (AFB <25 years, AFB 25-29
years, AFB 30-34 years, AFB ≥35 years, parity (1, 2, 3,
or ≥4) and PMH use (never, past user, current estrogen
(E) <5 years, current estrogen and progesterone (E + P)
<5years, current other ≤10 years, current E 5-10 years
or current E+P 5-10 years). For analyses of duration of
PMH use by type of PMH, we included only PMH use
durations of ≤1 0y e a r sb e c a u s eP M Hu s el o n g e rt h a n
10 years was for the most part limited to E-alone formu-
lations. PMH use for women with use for >10 years was
censored. For the nonreproductive exposures, we mod-
eled recent body mass index (BMI) (<21, 21 to <23, 23
to <25, 25 to <30 or ≥30 kg/m
2), BMI at age 18 (<19,
19-21, 21 to <23 or ≥23 kg/m
2)a n da l c o h o lc o n s u m p -
tion (0, <5, 5 to <15 or ≥15 g/day) as categorical vari-
ables. Continuous variables were used to assess P trend.
Family history of breast cancer in a first-degree relative
and personal history of BBD were modeled as binary
variables (yes or no). We carried forward the last self-
reported exposure data for one cycle if the data were
missing. Otherwise, women with missing information
were included in the analysis using indicators for the
missing variables. Findings were similar in analyses
including only nonmissing data (complete case analysis).
We used Cox proportional hazards regression strati-
fied by time period to model the incidence rate ratio
(RR) and 95% confidence interval (CI) of invasive cancer
overall for each exposure. We then restricted the analy-
sis to cases with ductal or lobular histology and used
Cox proportional hazards regression stratified by type of
outcome and time period to allow for different associa-
tions by histologic subtype [14]. We used data augmen-
tation, such that each participant had a separate
observation for each subtype. We coded the event vari-
able as 1 (failed) if the participant was diagnosed with
the histologic subtype corresponding to that data row,
and as 0 otherwise; cases were censored for the other
subtypes at the time of diagnosis.
We compared a model that assumed different associa-
tions for all exposures by histologic subtype (full model)
to a model with a single estimate across histologic sub-
types for one exposure at a time (reduced model). We
calculated the P value for heterogeneity (P-het) using a
likelihood ratio test, with the degrees of freedom equal
to the difference between the number of parameters in
the full and reduced models. Using a stepwise-down
approach, we set exposures with a nonsignificant P-het
(P > 0.05) to have a single parameter estimate across
subtypes so that the final model estimated two separate
associations for exposures that differed significantly by
s u b t y p ea n das i n g l ep a r a m e t e re s t i m a t ef o ra l lo t h e r
exposures. In the current analysis, we show the results
from the model that allowed all the associations to vary
(full model). In secondary analyses, we also examined
these associations limited to ER-positive and PR-positive
tumors.
All analyses were conducted using SAS version 9.1
software (SAS Institute, Cary, NC, USA). All P values
were based on two-sided tests and were considered sta-
tistically significant if P ≤ 0.05.
Results
At baseline, our analysis included 37,127 postmenopau-
sal women and then expanded to 107,759 women by the
end of follow-up. During 1,774,075 person-years of fol-
low-up, we observed 6,226 incident cases of invasive
breast cancer. Of these, 4,655 were ductal and 659 were
lobular carcinomas (see Table 1 for characteristics by
case type). The remaining 1,002 were excluded because
of no pathology report (8%), no primary structure evi-
dent (1%), mixed ductal and lobular histologies (4%) or
unknown or other histology (1%).
Reproductive and hormonal exposures
There was no heterogeneity in the risk estimates for age,
nulliparity, parity, age at menopause or type of meno-
pause by histology (P-het = 0.18, 0.87, 0.35, 0.45 and
0.08, respectively) (Table 2). Although an inverse asso-
ciation with surgical menopause was observed for ductal
but not lobular cancers, the P-heterogeneity value was
not significant.
The associations with age at menarche, AFB and PMH
use differed significantly by histology (P-het = 0.03,
<0.001 and <0.001, respectively). Age at menarche was
inversely associated with risk of both ductal and lobular
cancers; however, the association was stronger for lobu-
lar cancers (2% vs. 8% decrease in risk for each year
increase in age at menarche, respectively).
Increasing AFB was associated with an increasing risk
of both ductal and lobular cancers, although the results
were stronger for lobular cancers (P-het < 0.001). For
example, compared with the reference group (that is,
parous women with an AFB <25), the RRs associated
with an AFB between 30 and 34 years old were 1.21
(95% CI, 1.09-1.35) and 2.31 (95% CI, 1.79-2.99) for
ductal and lobular cancers, respectively. There was sig-
nificant heterogeneity when modeling AFB and parity as
continuous variables (P-het = <0.001 and 0.02, respec-
tively). For ductal and lobular tumors, respectively, the
RRs for every 5-year increase in AFB were 1.12 (P trend
< 0.001) and 1.48 (P trend < 0.001), while the RRs for
each additional birth were 0.97 (P trend = 0.01) and
1.05 (P trend = 0.11).
There was significant heterogeneity for PMH use
across subtypes (P-het < 0.001). Compared to never
users, past use was not significantly associated with risk
of ductal or lobular breast cancer (RR = 1.05; 95% CI,
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tively). Current use of E alone for <5 years was asso-
ciated with a statistically significant increase in the risk
of lobular cancer (RR = 1.56; 95% CI, 1.01-2.42) but not
ductal cancer (RR = 1.07; 95% CI, 0.90-1.28), while use
of E alone for 5 to 10 years was associated with an
increased risk of both cancer types, albeit the risk for
lobular tumors was stronger (RR = 1.30; 95% CI, 1.17-
1.45; and RR = 1.76; 95% CI, 1.34-2.34, for ductal and
lobular cancers, respectively). Current E+P use was asso-
ciated with increased risks of both subtypes of breast
cancer, although we found a stronger RR for lobular
than ductal cancers within each duration category. Spe-
cifically, the RRs for <5 years of use vs. no use were
1.56 (95% CI, 1.36-1.78) for ductal cancer and 2.16 (95%
CI, 1.52-3.06) for lobular cancer, while the RRs for 5-10
years of use were 1.75 (95% CI, 1.57-1.95) and 3.12
(95% CI, 2.41-4.05) for ductal and lobular cancers,
respectively.
Nonreproductive exposures
BMI was positively associated with risk of both subtypes
(P-het = 0.20) (Table 2). Compared to women with BMI
<21, women with BMI ≥30 had RRs of 1.60 (95% CI,
1.42-1.80) and 1.47 (95% CI, 1.08-2.00) for ductal and
lobular cancers, respectively. In contrast, BMI at age 18
was inversely associated with risk of both subtypes (RR
≥23 vs. 19 to <21 = 0.74; 95% CI, 0.67-0.81 for ductal;
and 0.69; 95% CI, 0.54-0.88 for lobular cancers; P-het =
0.16). For each five-unit increase in BMI at age 18, there
was a significant 23% and 22% decrease in risk of ductal
and lobular cancers, respectively. We [15] and others
[16,17] have shown that obesity is more strongly asso-
ciated with breast cancer risk among women who have
never used PMH. In a supplementary analysis among
never users, there was significant heterogeneity in the
association between BMI and risk by tumor subtype
(P-het = 0.02) with a stronger positive association for
ductal vs. lobular tumors (RR, BMI ≥30 vs. <21 = 2.11;
95% CI, 1.71-2.60; and RR = 1.70; 95% CI, 0.97-2.98,
respectively). However, the sample size was reduced
(1,596 ductal and 177 lobular cases).
T h ep o s i t i v ea s s o c i a t i o n sf o rf a m i l yh i s t o r yo fb r e a s t
cancer and a personal history of BBD were similar
across the two subtypes (Table 2). There was suggestion
of a stronger positive association between increasing
daily alcohol intake and risk of lobular cancer (P-het =
0.11 for each five-unit increase).
ER and PR status
Since lobular tumors are more likely to be ER-positive
and PR-positive than ductal cancers, we restricted ana-
lyses to ER-positive and PR-positive tumors in second-
ary analyses to address whether our observations were
driven by differential proportions of hormone receptor
positivity between ductal and lobular tumors. A total of
2,233 tumors ER-positive and PR-positive tumors were
included in this analysis (Table 3). In general, the results
were similar to those we observed in the analysis among
all tumors. Among the reproductive and hormonal risk
factors, there were still significant differences for the
associations with age at menarche, AFB and PMH use,
but not for age, nulliparity, parity, age at menopause or
menopausal type (P-het ≥ 0.16). Nevertheless, there was
significant heterogeneity for the relationship with
increasing parity when we modeled this exposure con-
tinuously (P-het = 0.05). Similar to the analysis includ-
ing the entire cohort, the protective effect of parity was
Table 1 Baseline characteristics of invasive postmenopausal breast cancer cases and noncases in the Nurses’ Health
Study in 1980
Noncases
(n = 101,533)
All invasive cases
(n = 6,226)
Ductal carcinoma
(n = 4,655)
Lobular carcinoma
(n = 659)
Reproductive or hormonal characteristics
Mean age (yr) 53.7 54.5 54.5 54.4
Mean age at menarche (yr) 12.7 12.6 12.6 12.5
Mean parity among parous women 3.3 3.2 3.2 3.3
Mean age at menopause (yr)
a 48.7 49.5 49.4 49.7
Ever used postmenopausal hormones (%) 47 48 50 51
Natural menopause (%) 64 67 67 66
Nonreproductive characteristics
Mean body mass index (kg/m
2) 24.9 25.2 25.2 24.5
Mean body mass index at age 18 (kg/m
2) 21.4 21.0 21.0 21.2
Median alcohol intake (g/day) 1.8 1.8 1.8 1.8
Family history of breast cancer in first degree
relative (%)
b
81 3 1 4 1 1
History of benign breast disease (%) 22 27 27 30
aAmong those who experienced natural menopause.
bFamily history in 1982.
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cancer by histologic subtype among 107,759 women in the Nurses’ Health Study
a
Ductal (n = 4,655) Lobular (n = 659)
Reproductive or hormonal exposures Cases (n) RR (95% CI) Cases (n) RR (95% CI) P-heterogeneity
b
Age (per year)
c 4,655 1.03 (1.03-1.04) 659 1.04 (1.03-1.06) 0.18
Age at menarche (per year)
c 4,655 0.98 (0.96-1.00) 659 0.92 (0.87-0.97) 0.03
Parous 4,220 1.00 (ref) 610 1.00 (ref)
Nulliparous 437 1.26 (1.12-1.41) 49 1.22 (0.87-1.71) 0.87
Age at first birth (AFB)
AFB < 25 2,354 1.00 (ref) 268 1.00 (ref)
AFB 25-29 1,741 1.11 (2.04-1.19) 282 1.63 (1.37-1.96)
AFB 30-34 425 1.21 (1.09-1.35) 86 2.31 (1.79-2.99)
AFB ≥35 137 1.31 (1.10-1.57) 23 2.10 (1.35-3.26) <0.001
AFB, continuous, RR (P trend)
c 1.12 (<0.001) 1.48 (<0.001) <0.001
Parity
Parity = 1 813 1.00 (ref) 100 1.00 (ref)
Parity = 2 1,171 0.99 (0.91-1.07) 180 0.94 (0.76-1.16)
Parity = 3 1,269 1.04 (0.96-1.13) 163 0.88 (0.71-1.09)
Parity ≥ 4 1,404 0.91 (0.82-1.00) 216 0.96 (0.75-1.24) 0.35
Parity, continuous, RR (P trend)
d 0.97 (0.01) 1.05 (0.11) 0.02
Postmenopausal hormone use
Never used 1,616 1.00 (ref) 181 1.00 (ref)
Past use 1,165 1.05 (0.97-1.14) 150 1.11 (0.88-1.39)
Current use, estrogen alone < 5 years 143 1.07 (0.90-1.28) 24 1.56 (1.01-2.42)
Current use, estrogen plus progesterone < 5 years 283 1.56 (1.36-1.78) 42 2.16 (1.52-3.06)
Current use, other ≤10 years 267 1.31 (1.15-1.49) 46 1.95 (1.40-2.71)
Current use, estrogen alone 5-10 years 518 1.30 (1.17-1.45) 93 1.76 (1.34-2.34)
Current use, estrogen + progesterone 5-10 years 463 1.75 (1.57-1.95) 99 3.12 (2.41-4.05) <0.001
Estrogen alone, continuous, RR (P trend)
e 1.00 (0.008) 1.00 (0.24) 1.00
Estrogen + progesterone, continuous, RR (P trend)
e 1.02 (<0.001) 1.03 (<0.001) 0.43
Other, continuous, RR (P trend)
e 1.00 (0.45) 1.01 (0.30) 0.52
Age at menopause (per year)
c 4,655 1.01 (1.00-1.01) 659 1.01 (1.00-1.02) 0.45
Menopausal type
Natural or radiation-induced 2,958 1.00 (ref) 391 1.00 (ref)
Surgical with two ovaries removed 667 0.80 (0.73-0.89) 101 1.00 (0.78-1.29)
Surgical with one or no ovaries removed 559 0.87 (0.79-0.96) 100 1.21 (0.95-1.53) 0.08
Nonreproductive exposures
Body mass index (BMI)
<21 473 1.00 (ref) 70 1.00 (ref)
21 to less than 23 719 1.15 (1.02-1.29) 104 1.11 (0.82-1.50)
23 to less than 25 858 1.21 (1.08-1.35) 122 1.14 (0.85-1.54)
25 to less than 30 1,590 1.41 (1.27-1.57) 225 1.33 (1.01-1.75)
≥30 926 1.60 (1.42-1.80) 124 1.47 (1.08-2.00) 0.20
BMI, continuous, RR (P trend)
f 1.14 (<0.001) 1.12 (0.009) 0.75
BMI at age 18
<19 839 1.07 (0.98-1.16) 114 1.00 (0.79-1.25)
19 to less than 21 1,506 1.00 (ref) 221 1.00 (ref)
21 to less than 23 959 0.83 (0.77-0.90) 148 0.88 (0.71-1.09)
≥23 744 0.74 (0.67-0.81) 99 0.69 (0.54-0.88) 0.16
BMI at age 18, continuous, RR (P trend)
f 0.77 (<0.001) 0.78 (0.003) 0.80
Alcohol intake (g/day)
0 2,552 1.00 (ref) 334 1.00 (ref)
<5 876 1.15 (1.06-1.24) 131 1.30 (1.05-1.59)
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ductive exposures, there was significant heterogeneity
for the association with BMI at 18 years of age (P-het =
0.03) and increasing daily alcohol intake (P-het = 0.02),
with a stronger association for lobular cancers but no
heterogeneity of effect for adult BMI, family history of
breast cancer or history of BBD (P-het ≥ 0.07).
Discussion
The results from this large prospective study further
substantiate that well-established breast cancer risk fac-
tors differentially affect risk on the basis of tumor histol-
ogy. Specifically, age at menarche, AFB and PMH use
were more strongly associated with lobular versus ductal
tumors, while there was no evidence for heterogeneity
for age at menopause, nulliparity, parity, menopausal
type, alcohol consumption, adult BMI, BMI at age 18,
family history of breast cancer and a personal history of
BBD. Collectively, these data suggest different etiologies
among the tumor subtypes and that lobular carcinomas
may represent a more hormonally responsive subtype.
When our analysis was limited to ER-positive and PR-
positive tumors, the findings were maintained, suggest-
ing true differences in the underlying tumor biology and
not a result of differential rates of ER and PR positivity.
A recent prospective analysis examined reproductive
and hormonal factors and risk of breast cancer by his-
tology among 17,923 ductal and 3,332 lobular cancers
from the Million Women Study [18]. Similar to our
results, the effect of age at menarche was greater for
lobular compared with ductal tumors (RR per 5-year
increase = 0.65 for lobular and 0.93 for ductal). Further,
in the Reeves et al. [18] meta-analysis of six cohort and
three case control studies, the summary estimates were
similar. No formal tests for heterogeneity were per-
formed. Although suggestive of differences in the effect
of age at menarche by histologic subtype, most studies
had low power and only one study was restricted to
postmenopausal women [19]. Overall, prior studies and
our observations support a stronger protective effect of
a later age at menarche for lobular cancer.
The overall RRs for AFB ≥30 vs. <20 from a meta-ana-
lysis of nine studies (six cohort and three case control)
were 1.24 for ductal cancer and 1.66 for lobular cancer;
however, individually, most studies had limited power,
and only the Million Women Study reported a statisti-
cally significant difference in the RRs by subtype [18].
Phipps et al. [20] recently reported no difference in risk
with AFB across subtypes. In our analysis, nulliparity
was associated with an increased risk of both cancer
subtypes, while we observed significant heterogeneity in
the association only for AFB, but not for parity per se.
When we modeled the continuous values, the P trend
for increasing parity was significant only for ductal
tumors; however, the effect of AFB was strongest for
lobular tumors. We cannot preclude that the discre-
pancy between the categorical and continuous results
for parity may be attributed to residual confounding by
AFB, which does not occur when modeled as categorical
or nonoverlapping variables. In other words, it may be
that women with higher parity are also likely to have a
later AFB. Our RR estimates for a 5-year delay in AFB
were 1.48 for lobular cancer vs. 1.12 for ductal cancer.
Other studies have reported no difference in risk for
parity by subtype [18,21,22]. Prior reports are in agree-
ment with our findings regarding parity. A recent pro-
spective analysis including 1,211,238 women reported a
lower risk of ductal but not lobular cancers with parity
[20]. Two additional reports have suggested that increas-
ing parity was associated with decreased risk of ductal
but not lobular cancers, although one study did not
report P values [23] and the association was not statisti-
cally significant in the second study [24]. On the basis
of our data and prior data, a later AFB and not parity
per se may play an important etiological role for lobular
cancers, while both AFB and number of births appear to
Table 2 Association between various reproductive and nonreproductive exposures and risk of postmenopausal breast
cancer by histologic subtype among 107,759 women in the Nurses’ Health Study
a (Continued)
5 to less than 15 765 1.22 (1.12-1.32) 113 1.34 (1.08-1.67)
≥15 462 1.31 (1.19-1.45) 81 1.75 (1.36-2.24) 0.20
Alcohol intake, continuous, RR (P trend)
g 1.04 (<0.001) 1.07 (<0.001) 0.11
Family history of breast cancer
No 3,805 1.00 (ref) 544 1.00 (ref)
Yes 850 1.55 (1.44-1.67) 115 1.41 (1.15-1.73) 0.39
Personal history of benign breast disease
No 2,294 1.00 (ref) 298 1.00 (ref)
Yes 2,361 1.47 (1.38-1.56) 361 1.60 (1.37-1.88) 0.32
aEstimates adjusted for all variables presented in the table.
bP value from likelihood ratio test comparing, for each covariate, the model with separate estimates
for the ductal and lobular histologic subtypes to the model with a single estimate across the two subtypes.
cRisk ratio (RR) for each 5-year increase in age among
parous women.
dRR for each child among parous women.
eRR for each 5-year increase in use.
fRR for each five-unit increase in BMI (kg/m
2).
gRR for each five-unit
increase in daily alcohol consumption (g/day). 95% CI, 95% confidence interval.
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Page 6 of 11Table 3 Association between various reproductive and non-reproductive exposures and risk of postmenopausal breast
cancer by histologic subtype among 107,759 women in the Nurses’ Health Study, ER-positive and PR-positive tumors
only
a
Ductal (n = 4,655) Lobular (n = 659)
Reproductive or hormonal exposures Cases (n) RR (95% CI) Cases (n) RR (95% CI) P-heterogeneity
b
Age (per year)
c 1,947 1.03 (1.02-1.04) 286 1.04 (1.02-1.06) 0.71
Age at menarche (per year)
c 1,947 0.99 (0.96-1.02) 286 0.87 (0.80-0.95) 0.005
Parous 1,795 1.00 (ref) 276 1.00 (ref)
Nulliparous 200 1.17 (0.94-1.47) 17 0.90 (0.47-1.72) 0.45
Age at first birth (AFB)
AFB < 25 1,040 1.00 (ref) 111 1.00 (ref)
AFB 25-29 730 1.06 (0.95-1.17) 131 1.82 (1.39-2.38)
AFB 30-34 174 1.09 (0.92-1.29) 41 2.62 (1.78-3.88)
AFB ≥35 51 1.02 (0.76-1.37) 10 2.10 (1.04-4.21) <0.001
AFB, continuous, RR (P trend)
c 1.11 (0.004) 1.56 (<0.001) <0.001
Parity
Parity = 1 360 1.00 (ref) 48 1.00 (ref)
Parity = 2 476 0.82 (0.68-0.99) 72 0.71 (0.46-1.10)
Parity = 3 545 0.90 (0.75-1.08) 69 0.71 (0.45-1.11)
Parity ≥ 4 614 0.80 (0.67-0.97) 104 0.94 (0.61-1.46) 0.09
Parity, continuous, RR (P trend)
d 0.98 (0.15) 1.06 (0.12) 0.05
Postmenopausal hormone use
Never used 738 1.00 (ref) 90 1.00 (ref)
Past use 549 1.09 (0.97-1.22) 73 1.18 (0.85-1.63)
Current use, estrogen alone < 5 years 59 1.01 (0.77-1.32) 12 1.64 (0.88-3.05)
Current use, estrogen plus progesterone < 5 years 155 1.74 (1.45-2.08) 29 2.95 (1.90-4.57)
Current use, other ≤10 years 91 1.28 (1.03-1.59) 14 1.82 (1.05-3.17)
Current use, estrogen alone 5-10 years 118 1.36 (1.11-1.67) 26 2.49 (1.57-3.97)
Current use, estrogen + progesterone 5-10 years 180 2.05 (1.73-2.43) 35 3.37 (2.23-5.08) <0.001
Estrogen alone, continuous, RR (P trend)
e 1.00 (0.006) 1.00 (0.63) 0.53
Estrogen + progesterone, continuous, RR (P trend)
e 1.03 (<0.001) 1.03 (<0.001) 0.24
Other, continuous, RR (P trend)
e 1.00 (0.71) 1.01 (0.36) 0.44
Age at menopause (per year)
c 1,947 1.00 (1.00-1.01) 286 1.02 (1.00-1.03) 0.16
Menopausal type
Natural or radiation-induced 1,337 1.00 (ref) 185 1.00 (ref)
Surgical with two ovaries removed 194 0.75 (0.64-0.88) 29 0.89 (0.59-1.36)
Surgical with one or no ovaries removed 202 0.86 (0.73-1.00) 35 1.10 (0.75-1.60) 0.63
Nonreproductive exposures
Body mass index (BMI)
<21 178 1.00 (ref) 26 1.00 (ref)
21 to less than 23 251 1.05 (0.87-1.27) 37 1.08 (0.66-1.78)
23 to less than 25 347 1.27 (1.06-1.52) 51 1.32 (0.82-2.11)
25 to less than 30 677 1.54 (1.30-1.82) 98 1.49 (0.96-2.31)
≥30 465 2.00 (1.67-2.39) 67 1.87 (1.16-3.01) 0.23
BMI, continuous, RR (P trend)
f 1.23 (<0.001) 1.25 (<0.001) 0.79
BMI at age 18
<19 355 1.18 (1.04-1.35) 51 1.42 (0.97-2.01)
19 to less than 21 593 1.00 (ref) 76 1.00 (ref)
21 to less than 23 399 0.84 (0.74-0.95) 71 1.22 (0.89-1.67)
≥23 354 0.81 (0.71-0.93) 49 0.89 (0.61-1.30) 0.03
BMI at age 18, continuous, RR (P trend)
f 0.80 (<0.001) 0.81 (0.08) 0.95
Alcohol intake (g/day)
0 1,062 1.00 (ref) 148 1.00 (ref)
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Page 7 of 11be important for ductal carcinomas. Similar to our find-
ings, most prior reports of the relationship between age
at menopause or menopausal status and risk have
reported no significant heterogeneity by histology
[18,21,23,25,26].
To date, 10 case control and 7 cohort studies have
examined the relationship between PMH use and risk of
developing ductal and lobular carcinoma [7,20]. Of
these, all but two cohort studies reported a stronger
increased risk for lobular compared with ductal carci-
noma [27,28]. In general, most studies have shown that
combined E+P was more strongly related to risk of lob-
ular vs. ductal carcinoma than use of E alone [7,29].
Lobular cancers are more likely to be ER-positive and/
or PR-positive than ductal tumors [30,31]. Thus, it is
not surprising that the effect of PMH may be strongest
for a hormone receptor-positive tumor. In fact, a recent
s t u d yr e p o r t i n gad e c r e a s ei nt h ei n c i d e n c eo fi n v a s i v e
cancers, particularly a decline in lobular carcinomas
[32], attributed this change to the concurrent decrease
in PMH use [33] following publication of the results
from the Women’s Health Initiative [34]. Unlike what
we observed among all tumors, the association with
PMH did not differ significantly by histologic subtype
when restricted to ER-positive and PR-positive lobular
and ductal tumors; however, this could be attributed to
the smaller case numbers, since the association was still
suggestively stronger for lobular tumors.
Fewer studies have examined the relationship between
duration of hormone use and risk [7,23,29,35-38]. In the
Million Women Study, Reeves et al. [29] reported no sig-
nificant difference in risk of ductal, lobular or tubular
cancer with increasing duration of use. Results from the
French E3N cohort also suggested no significant hetero-
geneity [38]. Calle et al. [7] reported an increased risk
with ≥2 years of use among current users for both ductal
and lobular cancers. In contrast, E alone was associated
with an increased risk of lobular cancer after 5 years of
use, but not with risk of ductal cancer; however, use of E
alone for 5-10 years was associated with risk of both can-
cer types, although the association was stronger for lobu-
lar tumors. Similarly, Li et al.[ 3 5 ]d o c u m e n t e da n
increased risk of both histologic subtypes with ≥3y e a r s
of use of E+P. Other case control studies have also found
an increased risk of lobular cancer with longer duration
of combined E+P use [10,36,37]. With our large study
population and repeated assessment of PMH use, our
study is adequately powered to assess a role of both tim-
ing and duration of PHH use. We similarly observed a
stronger association with use of combined E+P and the
lobular type. Although there was no significant heteroge-
neity in the results when we modeled PMH duration as a
continuous variable, this was expected, since we pre-
viously reported that breast cancer risk is increased only
with long-term use (for example, at least 5 years) [39].
Nonetheless, others have shown a significant increase in
risk with shorter durations of use [7,28,40].
Epidemiological studies have demonstrated a positive
association between BMI and postmenopausal breast
cancer risk [41], although for the most part anthropo-
metric factors appear to be similarly related to risk by
histology in some [8,25] but not all studies [42]. Despite
t h i s ,B M Iw a sm o r es t r o n g l ya s s o c i a t e d ,a l t h o u g hn o t
statistically different, with ductal cancer compared with
lobular cancer in one study [21], while another group
reported an inverse association between BMI and mixed
ductal-lobular carcinomas (P-het = 0.008), but no signif-
icant associations for the other subtypes [26]. We did
not observe significant heterogeneity for the association
between BMI and risk of cancer by subtype.
To our knowledge, ours is the first study that has
evaluated an association between BMI at age 18 and risk
Table 3 Association between various reproductive and non-reproductive exposures and risk of postmenopausal breast
cancer by histologic subtype among 107,759 women in the Nurses’ Health Study, ER-positive and PR-positive tumors
only
a (Continued)
<5 358 1.16 (1.03-1.31) 47 1.11 (0.80-1.55)
5 to less than 15 341 1.40 (1.23-1.58) 51 1.52 (1.10-2.10)
≥15 186 1.37 (1.17-1.61) 40 2.28 (1.60-3.24) 0.07
Alcohol intake, continuous, RR (P trend)
g 1.05 (<0.001) 1.12 (<0.001) 0.02
Family history of breast cancer
No 1,553 1.00 (ref) 227 1.00 (ref)
Yes 394 1.71 (1.53-1.91) 59 1.80 (1.35-2.39)
Personal history of benign breast disease 0.76
No 972 1.00 (ref) 142 1.00 (ref)
Yes 975 1.43 (1.30-1.56) 144 1.41 (1.10-1.78) 0.91
aEstimates adjusted for all variables presented in the table.
bP value from likelihood ratio test comparing, for each covariate, the model with separate estimates
for the ductal and lobular histologic subtypes to the model with a single estimate across the two subtypes.
cRisk ratio (RR) for each 5-year increase in age among
parous women.
dRR for each child among parous women.
eRR for each 5-year increase in use.
fRR for each five-unit increase in BMI (kg/m
2).
gRR for each five-unit
increase in daily alcohol consumption (g/day).
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In general, adolescent obesity is inversely associated
with breast cancer risk [41]. In a prospective analysis of
the NHS, we previously reported that higher BMI at age
18 was associated with lower breast cancer incidence
prior to and after menopause [15]. In the current study,
the inverse association between BMI at 18 was similar
for ductal and lobular cancers.
Two prior studies reported a significant positive asso-
ciation between alcohol consumption and risk of breast
cancer overall, which was stronger for lobular compared
with ductal cancer among postmenopausal women
(odds ratio (OR) = 1.8 vs. 1.2 [43] and 1.5 vs. 1.2 [26]
for lobular and ductal cancers, respectively). In a third
study, Rosenberg et al. [23] found a strong association
between alcohol consumption and risk of tubular but
not ductal or lobular cancers. Although we did not
observe significant heterogeneity between daily alcohol
consumption and risk overall, we did observe a positive
association between increasing intake and risk which
was suggestively stronger for lobular cancers (P-het =
0.11). Despite these findings, there was significant
heterogeneity for this association when we limited the
analysis to ER-positive and PR-positive tumors (P-het =
0.02). Given the inconsistent results, further research is
needed for this exposure.
In our analysis, family history of breast cancer and a
personal history of BBD were similarly associated with
increased risk of breast cancer, regardless of subtype.
Three prior studies have evaluated the relationship
between family history and risk by histology [9,20,26].
Recently, Phipps et al. [20] reported similar positive
associations across subtypes in their cohort study. In a
population-based case control analysis, family history
was associated with a twofold increased risk of breast
cancer across all histologic subtypes except for muci-
nous tumors [26], while family history was similarly
associated with a two- to threefold increase in risk of all
subtypes except for tubular carcinomas [9]. No confi-
dence intervals or formal tests for heterogeneity were
reported in the latter study. To our knowledge, two
prior studies have evaluated the relationship between
BBD and breast cancer risk stratified by histologic sub-
type [20,23]. A previous operation for BBD was asso-
ciated with a slightly higher risk of lobular cancer (OR =
1.9) compared with ductal cancer (OR = 1.5), although
this difference did not achieve statistical significance. In
contrast, a recent cohort study found similar significant
positive associations with BBD across subtypes with
increasing density (hazard ratio for highest density vs.
reference for both ductal and lobular cases was 1.62)
[20]. On the whole, there do not appear to be large dif-
ferences in the relationship between family history of
breast cancer or personal history of BBD by histology.
Overall, the relationship between the exposures evalu-
ated in the current study and the risk of breast cancer
was within the expected range and both subtypes
showed similar directions; however, the associations for
age at menarche, AFB and PMH use were stronger for
risk of lobular vs. ductal tumors. Since lobular tumors
are more often hormone receptor-positive, it is not
entirely unexpected that various hormonal or reproduc-
tive risk factors may be more strongly associated with
this subtype. The proposed mechanism underlying the
association between an earlier age at menarche and risk
likely is via its effect on the number of lifetime ovulatory
cycles, which in turn influences lifetime exposure to
endogenous ovarian hormones [44]. Parity not only
leads to substantial changes in hormone levels but also
induces differentiation of terminal duct lobular units,
making the breast epithelial cells less susceptible to car-
cinogenic insult [45]. Given that both exogenous and
endogenous hormones have been shown to strongly
influence breast cancer risk, an altered sex hormone
profile associated with PMH use as an exogenous hor-
mone source would also be expected to increase risk
[2]. Collectively, the data suggest that lobular breast
tumors are more hormonally responsive than ductal
breast tumors, thus making this histologic subtype more
responsive to hormonal stimulation [9]. Furthermore,
exposure to reproductive hormones (that is, estrogen or
progesterone) has been shown to promote lobular rather
than ductal differentiation, subsequently increasing the
number of lobular cells at risk [9]. In addition, various
groups have shown differences in gene expression
between these two histologic subtypes, providing insight
into the biology of these tumors, which may in turn be
utilized as diagnostic or therapeutic targets [46,47].
Future studies should continue to investigate the biolo-
gical basis for the reported differential relationships.
Major strengths of our study include the large number
of participants and high participation rate, resulting in
adequate statistical power to conduct stratified analyses.
Further, the prospective nature of the NHS cohort
allows for the analysis of repeated measures of most
exposures and confounders, limiting the effect of mea-
surement error. In addition, the methods used in this
analysis allowed for the estimation of separate associa-
tions with each subtype simultaneously, as well as for-
mal tests for differences in risk across subtypes.
Although our analysis included a large number of inva-
sive breast cancer cases, we did not have enough cases
to assess risk with less common histologic subtypes (for
example, tubular). Further, our analysis of ER-positive
and PR-positive tumors was less well-powered, given
that hormone receptor status was not available for all
cases. An additional limitation was that we classified
histologies on the basis of a review of pathology reports
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Page 9 of 11and did not conduct a centralized pathology review.
This could lead to nondifferential misclassification of
tumor histology and attenuate the associations.
Conclusions
In summary, the results fromt h i ss t u d yp r o v i d ee v i -
dence that some reproductive or hormonal and nonre-
productive factors are differentially associated with risk
of postmenopausal breast cancer on the basis of histolo-
gic subtype. For the most part, our results are consistent
with prior reports, complementing the growing body of
evidence suggesting etiologic heterogeneity between
ductal and lobular tumors. Future risk factor analyses
should continue to investigate associations stratified by
histology.
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